These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 26846209

  • 1. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.
    Bowker KE, Noel AR, Tomaselli S, MacGowan AP.
    J Antimicrob Chemother; 2016 May; 71(5):1270-8. PubMed ID: 26846209
    [Abstract] [Full Text] [Related]

  • 2. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A, Tomaselli S, Noel A, Bowker K.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):762-769. PubMed ID: 28039276
    [Abstract] [Full Text] [Related]

  • 3. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA, Crandon JL, Williams G, Nicolau DP.
    Int J Antimicrob Agents; 2014 Dec 01; 44(6):508-13. PubMed ID: 25278330
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Bowker KE.
    Antimicrob Agents Chemother; 2013 Jun 01; 57(6):2451-6. PubMed ID: 23459495
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
    Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2012 May 01; 56(5):2576-80. PubMed ID: 22330908
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
    Zhanel GG, Yachison C, Nichol K, Adam H, Noreddin AM, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2012 Jul 01; 67(7):1706-11. PubMed ID: 22467630
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.
    Antimicrob Agents Chemother; 2011 Apr 01; 55(4):1436-42. PubMed ID: 21263054
    [Abstract] [Full Text] [Related]

  • 9. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS, Lee WS, Bai KJ, Lam C, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.
    J Microbiol Immunol Infect; 2015 Feb 01; 48(1):85-91. PubMed ID: 23973410
    [Abstract] [Full Text] [Related]

  • 10. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR, Bowker KE, Attwood M, MacGowan AP.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2411-2417. PubMed ID: 30020472
    [Abstract] [Full Text] [Related]

  • 11. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A.
    Int J Antimicrob Agents; 2011 Mar 01; 37(3):244-7. PubMed ID: 21236643
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.
    J Antimicrob Chemother; 2018 May 01; 73(5):1305-1313. PubMed ID: 29562340
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM.
    J Antimicrob Chemother; 2007 Aug 01; 60(2):300-11. PubMed ID: 17548456
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O, Cercenado E, Gimeno M, Marín M, Coronel P, Bouza E, Spanish Urinary Tract Infection Study Group (SUTIS).
    Diagn Microbiol Infect Dis; 2010 Jul 01; 67(3):251-60. PubMed ID: 20542206
    [Abstract] [Full Text] [Related]

  • 16. Response of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.
    Gu M, Zhang N, Zhang L, Xiong M, Yang Y, Gu X, Shen X, Ding H.
    BMC Vet Res; 2015 Jul 25; 11():169. PubMed ID: 26209108
    [Abstract] [Full Text] [Related]

  • 17. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2002 Feb 25; 55(1):22-60. PubMed ID: 11977920
    [Abstract] [Full Text] [Related]

  • 18. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
    Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2011 Jul 25; 55(7):3220-5. PubMed ID: 21518838
    [Abstract] [Full Text] [Related]

  • 19. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F, Nordmann P, Domínguez-Herrera J, López-Rojas R, Smani Y, Poirel L, Pachón J.
    Int J Antimicrob Agents; 2012 Mar 25; 39(3):251-4. PubMed ID: 22154856
    [Abstract] [Full Text] [Related]

  • 20. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
    Melchers MJ, van Mil AC, Mouton JW.
    Antimicrob Agents Chemother; 2015 Aug 25; 59(8):4521-5. PubMed ID: 25987635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.